SBUs Ben Luft brings Lyme expertise to seminal paper on bacterial genetics and evolution TBR News Media
View original post here:
SBUs Ben Luft brings Lyme expertise to seminal paper on bacterial genetics and evolution - TBR News Media
Tag Archives: media
YPrime Research Reveals User-Centric eCOA Technologies as Key to Overcoming Challenges in Endocrinology … – GlobeNewswire
MALVERN, Pa., June 25, 2024 (GLOBE NEWSWIRE) -- YPrime, the leading pioneer in clinical trial technology, today released a comprehensive research report titled Endocrinology Clinical Trials: Advancing Research with the Help of eCOA Technologies. The report, based on a survey of clinical trial professionals specializing in endocrinology research, emphasizes the critical role of user-centric eCOA (electronic clinical outcome assessment) technologies in addressing the unique challenges faced by the industry.
The answers to several survey questions highlight the importance of patient-centricity in endocrinology clinical trials:
"At YPrime, we understand that every therapeutic area has its own unique challenges and requirements," said Mike Hughes, Chief Product Officer at YPrime. "By closely collaborating with patients, site staff, and sponsors, we develop eCOA solutions tailored to the specific needs of endocrinology trials. Our user-centric approach ensures that our technologies are not only cutting-edge but also intuitive and easy to use, ultimately leading to better patient engagement, higher data quality, and faster study timelines."
The report also highlights the growing adoption of connected devices in endocrinology clinical trials, with 44% of respondents already leveraging these technologies, primarily for at-home patient monitoring and another 46% considering adoption. In related news, YPrime recently announced the launch of its groundbreaking glucometer functionality, which integrates seamlessly with its eCOA platform. Developed in close collaboration with patients living with diabetes, this innovative feature promises to transform clinical trials with blood glucose endpoints by delivering a patient-centric, intuitive, and connected experience.
Please visit the YPrime website for the full version of Endocrinology Clinical Trials: Advancing Research with the Help of eCOA Technologies. The report offers valuable insights and practical recommendations for clinical trial professionals looking to optimize their endocrinology studies with the help of eCOA technologies.
About YPrime At YPrime, we streamline the clinical trial journey with a configurable platform designed for speed, quality, and certainty. With 50% faster IRT startup times, up to 30% faster eCOA launch times, and quality standards 50% above the industry average, YPrime can help you solve for certainty. Discover how by visitingwww.yprime.com or emailing marketing@yprime.com.
Media Contact Terry Rehm Head of Thought Leadership and Public Relations, YPrime trehm@yprime.com862-288-0329
Aninfographic accompanying this announcement is available at:https://www.globenewswire.com/NewsRoom/AttachmentNg/3a9e66f2-0df1-4529-a9b4-91994c1fda44
Read more:
YPrime Transforms Endocrinology and Autoimmune Trials through New Glucometer and eCOA Integrated Functionality – GlobeNewswire
MALVERN, Pa., May 21, 2024 (GLOBE NEWSWIRE) -- YPrime, the leading pioneer in clinical trial technology, today announced the launch of its groundbreaking glucometer functionality designed to integrate seamlessly with its eCOA platform. This functionality, developed in close collaboration with patients living with diabetes, will transform endocrinology and autoimmune clinical trials by delivering a patient-centric, intuitive, and connected experience.
This release supports a wide selection of glucometer devices, enhancing YPrime's eCOA connected device strategy as the Company continues to expand device integrations to support multiple therapeutic areas. The new glucometer functionality addresses the unique needs of diabetes patients, sites, and clinical trial sponsors.
Key highlights include:
"We are thrilled to introduce this revolutionary glucometer functionality, born out of our commitment to patient-focused innovation," said Mike Hughes, Chief Product Officer of YPrime. "By listening closely to patients living with diabetes and leveraging our expertise in eCOA, we have created a solution that truly empowers patients and unlocks new possibilities for endocrinology clinical trials and any indication requiring blood glucose logs."
The YPrime Glucometer/eCOA functionality, developed in close collaboration with patients living with diabetes, delivers a patient-centric, intuitive, and connected experience.
YPrime's dedication to patient-centricity was evident throughout the development process of the glucometer functionality. The Company conducted in-depth interviews with patients and received valuable insights about their lived experiences to drive the feature's design and functionality. This collaborative approach ensures that the blood glucose monitoring functionality meets the real-world needs of its users. Automating data collection and transfer minimizes the burden on patients and site staff while ensuring data integrity.
In related news, YPrimerecently announcedan eCOA assessment for Tender Swollen Joint Count (TSJC), increasing the accuracy and efficiency of clinical trials for diseases that affect the joints. Visithttp://www.yprime.com/tsjcto learn how this user-centric functionality will reduce the burden for patients and site staff.
To learn more about how YPrime's eCOA enables industry leaders to solve for certainty or to request a demo, visit http://www.yprime.com/ecoa/.
About YPrime At YPrime, we streamline the clinical trial journey with a configurable platform designed for speed, quality, and certainty. With 50% faster IRT startup times, up to 30% faster eCOA launch times, and quality standards 50% above the industry average, YPrime can help you solve for certainty. Discover how by visitingwww.yprime.com or emailing marketing@yprime.com.
Media Contact Terry Rehm Head of Thought Leadership and Public Relations, YPrime trehm@yprime.com862-288-0329
See original here:
Prof. Jay Shendure Joins Somite Therapeutics as Scientific Co-founder – BioSpace
[[To comply with academic institution guidelines, the founders' academic affiliations and roles are listed only at the end of the statement.]]
BOSTON, May 21, 2024 /PRNewswire/ -- Somite Therapeutics, a tech-bio company harnessing big data and AI to pioneer novel cell replacement therapies, is thrilled to announce the addition of Prof. Jay Shendure as its newest Scientific Co-Founder.
Prof. Shendure, an HHMI Investigator and world leader in single-cell and functional genomic assays, has pushed the envelope on the scale of analyses that are possible today. He has developed massively parallel measurement approaches that solve open problems in biology and has increased the throughput of digital twin embryos by several orders of magnitude.
His addition to the team will help Somite advance its AI platform, AlphaStem, to develop cell replacement therapies for diseases such as diabetes, obesity, and muscular dystrophies.
"Our plan is to generate massive amounts of data to lay the foundation of our AI/ML platform, Alphastem," commented Dr. Micha Breakstone, Co-founder and CEO of Somite. "Prof. Shendure's addition marks a pivotal moment for our company as we continue to innovate and push the boundaries of what is possible in cell therapy."
About Prof. Jay Shendure
Jay Shendure, M.D., Ph.D. is an Investigator of the Howard Hughes Medical Institute, a Professor of Genome Sciences at the University of Washington, and Scientific Director of the Seattle Hub for Synthetic Biology (Allen-CZI-UW), the Allen Discovery Center for Cell Lineage Tracing, and the Brotman Baty Institute for Precision Medicine. His lab is known for the development and application of genomic technologies to outstanding challenges in genetics, molecular biology and developmental biology. Dr. Shendure is the recipient of the Curt Stern Award from the American Society of Human Genetics, the Richard Lounsbery Award from the National Academy of Sciences and the Mendel Award from the European Society of Human Genetics. He is also an elected member of the American Association for the Advancement of Science and the National Academy of Sciences. He received his MD and PhD degrees from Harvard Medical School.
About Somite
Somite.ai is a venture-backed company aiming to become the OpenAI of stem cell biology, developing AI foundation models to produce human tissue for cell therapies at scale for diseases such as diabetes, obesity, and muscular dystrophies. Somite's AI platform, AlphaStem, fuels a virtuous cycle: It enables new cell therapies, generating massive data that further improve the platform, empowering even faster therapy creation with broader applications.
Incorporated in Oct. 2023, Somite.ai has raised $5.3m to date.
Somite Management Team:
Scientific Co-founders:
Media Contact: media-relations@somite.ai Website: http://www.somite.ai
View original content to download multimedia:https://www.prnewswire.com/news-releases/prof-jay-shendure-joins-somite-therapeutics-as-scientific-co-founder-302149592.html
SOURCE Somite Therapeutics
Read the rest here:
Prof. Jay Shendure Joins Somite Therapeutics as Scientific Co-founder - BioSpace
World-first AI algorithm developed at CHEO leads to rare disease diagnosis for families – CHEO
Harnessing the power of artificial intelligence (AI), CHEO researchers have developed a groundbreaking search algorithm that identifies children and youth who may have an undiagnosed rare genetic disease and refers them for genetic testing putting an end to their diagnostic odyssey.
The ThinkRare algorithm is incredibly exciting and promising because it means we can help families find answers and get the care and support they need sooner, said Dr. Kym Boycott, Senior Scientist at the CHEO Research Institute and Chief of Genetics at CHEO. This algorithm is a game changer. Using AI to scour CHEOs electronic health record based on set criteria, ThinkRare can accurately identify kids who may have an undiagnosed rare genetic disease and refer them to our clinic something that may have never happened without it.
Ten-year-old Antony Wistaff and hisfamily have spentcountlesshours at CHEO, callingit a second home. Antony wasbornprematurely in October 2013 and a few dayslaterunderwent emergency surgery at CHEO to place a shunt for hydrocephalus. But thatwasonly the beginning of whatwouldbecome a decade-long diagnostic journeyconsisting of more than 100 outpatientappointmentsacross six differentspecialtyclinics at CHEO, and 30 trips to the emergency department for variousreasons.
That was until recently, when the ThinkRare algorithm identified Antony as potentially having an undiagnosed rare genetic disease and flagged him for a referral to receive genome-wide sequencing testing a test that simultaneously analyzes the more than 5,000 genes that have been associated with rare disease and is now available clinically in Ontario.
The results of the genetictestingdiscoveredthat Antony has Chung-Jansen Syndrome a rare disorderresultingfrom a pathogenic variant in the PHIP gene. At present, the syndrome has been diagnosed in only about 400 people worldwide and itexplainedmany of Antonyshealth and behavioural challenges, includinghisdevelopmentaldelays, learningdifficulties, and large head size.
When we found out that Antony was diagnosed with Chung-Jansen Syndrome, it answered so many questions for our family, said Georges Wistaff, Antonys dad. This research brought a kind of peace to our house. Hadweknownthissooner, itwould have meantlessquestioning as parents, less stress, and more support becausewewould have had a cleardiagnosis for Antony. A little bit of blood and a simple test, answeredsomany questions.
To date, Think Rare, whichiscurrently operating as a researchprojectapproved by the CHEO ResearchEthicsBoard, isthree for three meaning the first three patients identified by ThinkRare and referred to genetics have received test results and been diagnosedwith a rare disease. Genetictestingisunderway for manyotherfamiliesidentified by ThinkRare.
Our goal is to flip the diagnostic care journey on itshead and start withgenetictestingearlier on the care pathway. By incorporating the ThinkRarealgorithmintoclinical care, wewillbe able to support CHEO clinicians and frontlineworkerswith the power of machine learning to find the needle in the haystack, added Dr. Boycott, whois a Tier 1 Canada Research Chair in Rare DiseasePrecisionHealth and Professor of Pediatrics at the University of Ottawa.
Work iscurrentlyunderway at CHEO to transition the ThinkRareprojectfrom researchintoclinical practice, with all the necessary patient privacymechanisms in place.
CHEO isuniquelypositioned to develop an impactfulalgorithmsuch as ThinkRarebecause of CHEOsinvestment in a robustelectronichealth record system, ourcommitment to innovation, our close collaboration betweenclinical and researchteams, and becausewe are the only pediatric healthcare centre in Eastern Ontario serving a widegeographic area. At CHEO, we have broughttogether all the necessaryelementswhenitcomes to making AI advancements in healthcare, said Dr. Jason Berman, CEO and Scientific Director, CHEO Research Institute, and Vice-PresidentResearch, CHEO.
The ThinkRareprojectwas made possible withfundingfrom the CHEO Foundation, the CHAMO Innovation Fund, and Ontario Genomics.
-30-
Media contact:
Jennifer Ruff Director of Communications CHEO Research Institute (613) 261-3979 jruff@cheo.on.ca
About the CHEO Research Institute
The CHEO Research Institute is a global centre of excellence in pediatric research that connects talent and technology in pursuit of life-changing research for every child, youth and family in the CHEO community and beyond. The CHEO Research Institute coordinates the researchactivities of CHEO and isaffiliatedwith the University of Ottawa. At the CHEO Research Institute, discoveries inspire the best life for everychild and youth. For more information, visitcheoresearch.ca.
More here:
World-first AI algorithm developed at CHEO leads to rare disease diagnosis for families - CHEO
Phones and kids: new pediatric guidelines, expert advice and info on new school rules – Kidsburgh
Photo above by Julia Coimbra via Unsplash.
The first iPhones and Androids hit the market when todays high schoolers were babies. Theyve never known life without smartphones. And today, the Surgeon Generals office estimates that 95 percent of kids ages 13-17 and nearly 40 percent of kids ages 8-12 use social media, connect to the internet and use a massive array of interactive apps through their phones.
Until recently, the advice was to limit kids screen time to two hours per day or less. That wasnt always easy and were now discovering that it wasnt enough to just focus on the number of minutes kids spent in the glow of their screens. It matters what theyre watching and reading, and how it affects a given child or teen.
Phones connect our kids with information and ideas, but they also appear to be causing increases in anxiety, depression, bullying and other distractions, especially in the classroom.
How do parents help their kids navigate our digitally connected world?
Last month the American Academy of Pediatrics (AAP) Center of Excellence on Social Media and Youth Mental Health unveiled its 5 Cs of Media Use a guideline for parents to better understand media influences and to strive for healthy screen time habits (we break down all the details on that below). And schools have begun testing new rules and grappling with the growing issue of phones in schools at all grade levels.
Weve got all that information, along with info on how starter phones can help:
SCHOOLS TAKE ACTION
To help control negative effects from cell phone overuse, schools are increasingly invoking strict rules to eliminate phones in classrooms. And earlier this month, PA state senator Ryan Aument (RLancaster) drafted a bill to lock up student phones due to the steep decline in mental health in children since the early 2010s, according to his website.
Data from Common Sense Media also found that 97 percent of students surveyed used a phone on average for 43 minutes during school hours, and 37 percent of that time was spent on social media.
Starting this year, Sto-Rox School District banned cell phones in classrooms in all grades.
Heres how it works: Over the course of about 10 minutes, nearly 600 students in grades 7 through 12 enter their school building, hand their phones to a staff member who places it in an envelope with the childs name on it, then its put in a bin to be locked in storage for the day. The students then pass through metal detectors and head to breakfast. Phones are returned by the students last period teachers during the days final five minutes.
The process was planned carefully and has been running smoothly. We are very good at it, says Sto-Rox superintendent Megan Marie Van Fossan. Were very strategic.
And the impact? At the start of the school year, the students werent happy about the new policy. But then positive changes began surfacing.
Van Fossan says kids have begun talking to each other again in the cafeteria. Back when phones were allowed, the cafeteria was a relatively quiet place where students were focused on their phones rather than one another.Mornings in the hallway are now the same: Rather than scrolling on their phones or texting, students are greeting each other as the day begins.
Rather than revolving around social media, these students days are full of in-person interaction and connection. No parents have complained about the policy, Van Fossan says, and the rule isnt difficult to enforce.
Other school districts in the region have been taking notice.
We get phone calls and emails (from other school districts), saying, We are looking at going to this policy. Tell us about your experience, Van Fossan says.
Why ban phones?
Phones were taken out of seventh and eighth grade classrooms last year and were never permitted in kindergarten. But the choice to start a district wide ban came because of increasing safety and security concerns.
Kids were texting one another to meet, fight someone in the bathroom, hurt someone after school, Van Fossan says. We dont need that going on during the school day.
Students were also paying less attention in class.
Beyond helping with focus, the new system also helps inspire kids to be on time: Late students must drop off and retrieve their phones at the schools office, potentially adding 20 minutes to the end of their school day.
In the Pittsburgh Public Schools 54 buildings, the electronic device policy generally prohibits students from using, displaying or turning on cell phones on school grounds. And in some PPS high school buildings, student phones are sealed in pouches at the start of the day.
But in many buildings, students have traditionally kept their phones with them.
A lot of our high schools are leaning (toward) collecting phones; not every high school does, says Carrie Woodard, director of school counseling for the district.
In recent years, PPS counselors have seen increases in cyber bullying in addition to anxiety and depression symptoms in students who arrive at school upset from social media postings made after school hours.
Its something I think weve been battling for over a decade now, Woodard says.
What can help besides banning?
To help win that battle, Woodard said its important for educators and school counselors to support the whole child, academically and personally by:
Some parents, Woodard says, are anxious about phones being taken away from students. They want to have instant communication with their child in the event of an emergency.
From the school level, we can always assure them, she says, that if there is an emergency there are systems in place where the educational team will get in touch with the parent.
What is a starter phone?
Starter phones are entry-level devices that allow kids to text, call and store photos. Some have limited access to the Internet or social media. They come in many shapes and sizes, and are usually budget-friendly. Here are some options parents may want to pursue:
The Bark Android phone has parental controls included. It sends alerts about your childs texts and searches and has location tracking. Approval to download apps is necessary. You can also install a Bark parental control app on any smartphone. Plans starting at $39/month at Bark.us
Also an Android phone, the Pinwheel has parental controls built in, and there is no web browser so it has no direct access to social media. There are several models. Note that you wont receive alerts about messages that will be a potential problem. The Plus 3 is $489 on Amazon.
The iPhone SE lets parents manage how much screen time a child spends in their browser. Through Apples Family Sharing, parents set screen time permission, approve what their child buys or downloads, and can disable apps and set limits from their own device. Like almost any iPhone, it can be set up with Apples parental controls. Costs starts at $429 from Apple.
The TCL Flip 2 flip phone allows calling and messaging, and it includes simple games and a limited web browser. $100 from Amazon.
The Nokia 2780 Flip phone is easy to use for texting and calling. $90 at Best Buy.
The Gabb Phone has no internet or social media and no app store. It does include a GPS tracker, and other basics like a camera, calculator, photo album. $75 at Gabb.com.
SCREEN TIME ADVICE FOR EVERYONE
Last month the American Academy of Pediatrics (AAP) Center of Excellence on Social Media and Youth Mental Health unveiled its 5 Cs of Media Use a guideline for parents to better understand media influences and to strive for healthy screen time habits.
The AAP is looking for a way to help parents and educators understand the issues cropping up with phones and other screens, and understand how they can help the children in their lives, says Pamela Schoemer, MD of UPMC Childrens Community Pediatrics. Schoemer tells Kidsburgh she has discussions about screen time effects in about half of her patient visits.
The 5 Cs stand for:
The calm element of the guideline, Dr. Schoemer notes, typically comes up when there are issues with falling asleep something that can spill over into the ability to focus or even stay awake throughout the next school day.
Kids need the ability to calm themselves and to deal with their emotions, she said. So often I see parents, especially with younger kidsputting something (a cell phone or tablet) in front of their child to calm them.
Instead of handing kids a digital device, she suggests:
Dr. Schoemer considers that final C, communication, to be the best resource for parents. Its helpful to have discussions about time limits with devices. But communication isnt just about how many minutes a child is looking at a screen. Its also important to know what your child is looking at it and explore its impact.
Its okay to ask what your child is looking at, she says, and it might even lead to a moment of shared laughter:A TikTok can be just as funny to us as it is to them.
Valuable screen time, like exploring interests, communication with extended family or for schoolwork, is great. Healthy screen habits at home can include educational videos that help deal with emotions or those that encourage an activity, like cooking or science experiments for younger children. Anything on PBS Kids (from Mister Rogerss Neighborhood and Daniel Tigers Neighborhood to the friendship-focused show City Island) is suitable for younger children over the age of 2 or 3.
All screen time isnt equal, and you have to assess it, Schoemer says. If that young person is following an influencer or playing video games with more violence or rudeness or language that you dont approve of or, unfortunately, is being bullied, those are bad screen times.
One last note: Kids are smart and may manage to work around parental controls. So parents should check devices, and also educate themselves by consulting friends, pediatricians and other resources like the AAP website or Common Sense Media.
Read the rest here:
Phones and kids: new pediatric guidelines, expert advice and info on new school rules - Kidsburgh
The IT strategy behind a groundbreaking new $2B pediatric hospital – Healthcare IT News
Children's Healthcare of Atlanta Arthur M. Blank Hospital is scheduled to open this September. It was built from the ground up with the very latest healthcare information technology.
It is one of the largest and most advanced pediatric hospitals in the world. It cost more than $2 billion. It is 19 stories tall, with nearly two million square feet. It has 90 robots who have their own six elevators.
It features deep device integration, artificial intelligence, location awareness, video and patient engagement technology all focused on helping clinicians save steps and make better decisions while providing an excellent patient experience.
Jeremy T. Meller is chief information officer at Children's Healthcare of Atlanta Arthur M. Blank Hospital. We spoke with him to get the inside story of the creation of this facility's health IT strategy and the implementation of the very latest technologies.
Q. What was the overarching health IT strategy that went into creating the hospital from the ground up?
A. We are so proud of all the planning and work that has gone into Children's Healthcare of Atlanta Arthur M. Blank Hospital opening in September. The overall hospital visioning process began more than seven years ago. Children's worked with our Patient and Parent Advisory Council to understand what our families thought was most important for a new hospital.
We received so many valuable and creative responses that led to recommendations such as a second television in the room and washers and dryers on each floor. Our councils worked to understand the themes for what would make the most healing environment, with the best care possible for the kids we treat.
We also worked cross-functionally to learn about the leading practices in hospital design, understand pain points our staff were experiencing, and where we thought technology and innovation were headed in the future. But things move quickly. When we started the process in 2017, we assumed self-driving cars would need to be accommodated.
Meanwhile, we had no idea a global pandemic was on the horizon and we would be dealing with workforce issues. People were still confusing algorithmic bots with AI and nobody was talking about generative AI at all. We adapted our plans over the last few years to accommodate the new realities and needs we learned.
Our technology strategies started to form when we held massive-scale workflow simulations as part of our facility design process. Children's created "Cardboard City" by transforming a 100,000-square-foot warehouse into one of the largest, full-scale hospital mock-ups in the country. Using more than 12 miles of tape and 10,000 square feet of cardboard, our hospital planning and simulation teams built the mock-up to test drive the 3-D design plans and determine how the layouts might affect employee workflow, patient care and family experience.
Jeremy T. Meller, Children's Healthcare of Atlanta Arthur M. Blank Hospital
Through this process, we identified space requirements needed to be reworked in some areas, plug locations might be wrong, or we needed technology to help address an issue.
An example of this is the physical side of Arthur M. Blank Hospital. At nearly two million square feet, it rivals or exceeds many professional football stadiums in scale. This is in part because every patient room is spacious, with separate areas for parents. Parents will have a desk, a sofa bed, and their own television.
These amenities are sure to improve the quality of experience, but they also bring technology implications, such as increased network load. The physical size itself means moving around will simply take more time.
An extra 10,000 steps could impact the length of time it takes for a nurse to reach a patient room, so we were challenged to find ways that technology could help with communication, reduce steps (both physical and process steps), and improve the quality of care we were going to be providing.
Q. Were there special IT considerations because it is a pediatrics hospital?
A. Pediatric healthcare brings with it additional complexities in almost every way. Equipment must be sized for stages of anatomical childhood development. Care protocols are different and more complex.
Children respond differently to medical interventions, and most systems are not designed from the ground up to be oriented toward pediatric medicine. The electronic health record has more complexity, and providing access to patient records is more involved because a legal guardian relationship must be determined.
There are real-world reasons why pediatric hospitalizations are resource-intensive, but this doesn't mean finding experienced clinical staff and physicians is any easier. Our needs are more intensive, and we must do everything we possibly can to support our clinicians in providing the best care possible.
To help save physical steps and reduce time burden, we've integrated screens outside of each patient room with halo lights that change color depending on who is in the room. This is dependent on RTLS badges staff will wear once the hospital opens, and provides a visual clue that can reduce steps.
Locations are updated on status boards, and clinicians can review who is or was with the patient. This will help improve staff coordination, and in turn, patient care.
Q. You have 90 robots. Please talk about the place robotics holds in the hospital and what kinds of things they will be doing.
A. We are really excited about opening Arthur M. Blank Hospital with the world's largest fleet of robots. We will have two types of robots, autonomous mobile robots and Robos. About a third will be patient facing, helping to deliver meals or medications and pick up labs or other items that cannot go through the tube system.
Our back-hall "tugs" are designed with a platform to slide under specially designed carts that will haul heavy linen and trash. Arthur M. Blank Hospital has six elevators designed specifically for the robots. The system will include advanced algorithms and camera technology to determine location and bin utilization.
Logistical planning for the new hospital has been key for our teams as well. Our intelligent supply chain management system uses RFID technology to better automate stock and billing processes. Our pneumatic tube system has traffic-control monitoring, and our pressurized trash-chute system even has radiation monitoring.
Everything is connected. We have nearly 60 facility- and supply chain-related systems most of them are systems we have in other facilities, but at our new hospital they are networked, automated and monitored.
Q. You told me the hospital will feature deep device integration and artificial intelligence. Please elaborate.
A. Like many organizations, we have a long-term investment in predictive analytics but are more recently looking at how generative AI can be used in meaningful and safe ways. Everyone talks about how AI will change the world, change healthcare. But for AI to be useful, it needs to have content, it needs data. For predictive deterioration algorithms to be most effective, timely bio-physio data is needed.
Many hospitals have IT systems and medical equipment, but they aren't deeply integrated. A nurse will be standing at a computer, looking at a patient monitor (another computer) and keying in hourly vitals. This is an outmoded paradigm that needs to shift to real time.
We are integrating virtually every type of device that can provide this data, pulling it into our analytics systems, and currently are developing 11 predictive models to assist our clinical teams, helping them decide where to focus or make better, safer decisions.
Waveforms will be available to clinicians in real time on their mobile clinical smartphones, allowing them to better triage alarm response, such as seeing when a lead is disconnected. The nurse call system is integrated into our RTLS so alarms will auto-silence when a nurse enters the room.
Q. What kinds of patient engagement technologies do you have and what are the expected outcomes?
A. We know patients would probably rather be home than in the hospital, and that is why we've designed rooms that are all large and designed for the greatest comfort and connection for the whole family.
We will have multiple screens in each room. We will have the traditional patient education and entertainment screen, as well as a second TV for parents and a vertically mounted virtual whiteboard. The RTLS system will be integrated into the room, and when a clinician enters, a pop-up will appear on the television and whiteboard showing who just entered.
The whiteboard will provide information useful to the patient and family, including a daily schedule and a list of care team members. When the physician or nurse enters the room, the display will change, allowing the caregiver to pull up relevant information and radiology images to communicate with the patient.
A high-quality pan-tilt-zoom camera also is installed in every room and will allow caregivers, interpreters or even family members to dial into the room. It will turn away for privacy when not in use and all calls will be accepted or declined from the pillow-speaker.
Q. In the end, what are your goals as the CIO of this new high-tech hospital?
A. The new Arthur M. Blank Hospital will be one of the most advanced facilities in the world when it opens in September. My goal is we use technology to help clinicians provide the best care possible through more intelligent systems, save steps through improved communication and technology-supported visual processes, and improve care and experience through improved patient engagement.
Of course, we can't do anything in IT without an eye on cybersecurity, so that has been an integral part of everything we have done in advance of opening the hospital. All the new systems and capabilities have been carefully evaluated and implemented to provide the greatest safety and security possible.
Follow Bill's HIT coverage on LinkedIn: Bill Siwicki Email him:bsiwicki@himss.org Healthcare IT News is a HIMSS Media publication.
Continue reading here:
The IT strategy behind a groundbreaking new $2B pediatric hospital - Healthcare IT News
Biohaven Showcases Innovative Neuroscience Portfolio with 20 Presentations at the 2024 American Academy of … – PR Newswire
DENVER, CO and NEW HAVEN, Conn., April 13, 2024 /PRNewswire/ -- Biohaven Ltd.(NYSE: BHVN) announced today that 20 abstracts, including 8 oral presentations and 12 posters, will be featured this weekend starting April 13th at the 2024 American Academy of Neurology (AAN) Annual Meeting, taking place in Denver, Colorado. The presentations highlight Biohaven's leadership in neuroscience and extensive development programs evaluating novel therapies to treat neurological diseases, with abstracts covering programs that includeKv7 ion channel modulation, molecular degraders of extracellular protein (MoDEs), TRPM3 antagonism, TYK2/JAK1 inhibition, glutamate modulation, and myostatin inhibition.
Irfan Qureshi, M.D., Chief Medical Officer of Biohaven, commented, "The research being presented at the AAN Annual Meeting emphasizes Biohaven's commitment to developing new therapeutic options across a range of neurological diseases. By targeting novel mechanisms of action, differentiated from currently available treatments and other therapies in development, and following innovative science, Biohaven continues to strive for better treatments for people living with neurological disorders. We are particularly honored that the AAN Science Committee selected our BHV-2100 (TRPM3) abstract as an AAN Abstract of Distinction, recognizing it as the top abstract in the pain category. Following the completion of Phase 1 studies in the first half of 2024, we look forward to initiating a Phase 2 study with BHV-2100 in migraine in the second half of the year and are excited by the potential for this novel nonopioid approach to treat pain."
Vlad Coric M.D., Chief Executive Officer and Chairman of Biohaven, added, "Our leadership in neuroscience research is on full display at the AAN Annual Meeting with the breadth and depth of clinical, epidemiological, and preclinical programs highlighted in our scientific presentations. Central nervous system (CNS) disorders continue to represent one of the highest unmet medical needs facing our society and we must act urgently to bring better treatments to patients and improve clinical outcomes. We believe that the next generation of therapies for CNS disorders will include MoDEs for autoimmune disorders, ion channel modulation for epilepsy, migraine and other pain disorders, immune modulation for neurodegenerative disorders including Parkinson's and Alzheimer's diseases, myostatin targeting drugs for neuromuscular disorders and glutamate modulating agents for neuropsychiatric disorders. I am so proud of the team at Biohaven who are working tirelessly to alleviate the burden of these devastating disorders."
The complete list of Biohaven's accepted abstract titles is below. Full abstracts can be viewed online at https://index.mirasmart.com/AAN2024/.
Oral Presentations:
Poster Presentations:
Posters and presentations will be available on thePosters and Presentationspage after the conference atwww.biohaven.com.
About BiohavenBiohavenis a biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. The company is advancing its innovative portfolio of therapeutics, leveraging its proven drug development experience and multiple proprietary drug development platforms.Biohaven'sextensive clinical and preclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for immunological diseases; TRPM3 antagonism for migraine and neuropathic pain; TYK2/JAK1 inhibition for neuroinflammatory disorders; glutamate modulation for OCD and SCA; myostatin inhibition for neuromuscular and metabolic diseases, including SMA and obesity; and antibody recruiting, bispecific molecules and antibody drug conjugates for cancer.
Forward-looking StatementsThis news release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including "continue", "plan", "will", "believe", "may", "expect", "anticipate" and similar expressions, is intended to identify forward-looking statements. Investors are cautioned that any forward-looking statements, including statements regarding the future development, timing and potential marketing approval and commercialization of development candidates, are not guarantees of future performance or results and involve substantial risks and uncertainties. Actual results, developments and events may differ materially from those in the forward-looking statements as a result of various factors including: the expected timing, commencement and outcomes ofBiohaven'splanned and ongoing clinical trials; the timing of planned interactions and filings with the FDA; the timing and outcome of expected regulatory filings; complying with applicableU.S.regulatory requirements; the potential commercialization ofBiohaven'sproduct candidates; the potential forBiohaven'sproduct candidates to be first in class therapies; and the effectiveness and safety ofBiohaven'sproduct candidates. Additional important factors to be considered in connection with forward-looking statements are described inBiohaven'sfilings with theSecurities and Exchange Commission, including within the sections titled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations". The forward-looking statements are made as of the date of this news release, andBiohavendoes not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Investor Contact:Jennifer Porcelli Vice President, Investor Relations [emailprotected] 201-248-0741
Media Contact:Mike Beyer Sam Brown Inc. [emailprotected] 312-961-2502
MoDE is a trademark of Biohaven Therapeutics Ltd.
Biohaven AAN 2024 Oral & Poster Presentations:
Functional Impairments in Patients with KCNQ2-DEE: Associations Among Key Clinical Features Sunday 4/14/24: 8:00-9:00 P1- Poster Session 1 Colorado Convention Center Exhibit Hall B-E
The Phase 3 RESILIENT Study: Taldefgrobep Alfa in Spinal Muscular Atrophy Sunday 4/14/24: 11:45 - 12:45 P2 - Poster Session 2 Colorado Convention Center - Exhibit Hall
Association of Anti-inflammatory Therapy Use with the Incidence of Parkinson's Disease: A Person-Time Analysis Among Patients with Autoimmune Diseases Sunday 4/14/24: 1:00-3:00 (1:24-1:36) S2 Movement Disorders: Epidemiology and Clinical Aspects Colorado Convention Center- Mile High 4CD
Re-weighting MDS-UPDRS Motor Items for Optimal Sensitivity to Parkinson's Disease Progression in Untreated Patients Using Parkinson's Progression Markers Initiative Data Sunday 4/14/24: 1:00-3:00 (1:36-1:48) S2 Movement Disorders: Epidemiology and Clinical Aspects Colorado Convention Center- Mile High 4CD
Population Pharmacokinetic Modeling of Riluzole After Administration of a Next Generation Prodrug Troriluzole Sunday 4/14/24: 1:00 - 3:00 (2:12-2:24) S3 - General Neurology 1 Colorado Convention Center - Four Seasons 2/3
Next Generation Prodrug Troriluzole: Increased Bioavailability of Riluzole with No Food Effect in Healthy Subjects Sunday 4/14/24: 3:30 - 5:30 (4:30-4:42) S5 - ALS and CMT: New Therapeutic Approaches Colorado Convention Center - Four Seasons 1
BHV-2100, A First-In-Class TRPM3 Antagonist for the Treatment of Pain Monday 4/15/24: 11:15-12:15 (11:27-11:39) S13 Pain Research Colorado Convention Center 605
Troriluzole Exhibits Favorable Hepatic Safety Profile Across a Diverse Range of Disorders Monday 4/15/24: 11:45 - 12:45 P4 - Poster Session 4 Colorado Convention Center - Exhibit Hall
Safety, Tolerability, and Pharmacokinetics of Single and Multiple Rising Doses of a Next Generation Prodrug Troriluzole in Healthy Subjects Monday 4/15/24: 11:45 - 12:45 P4 - Poster Session 4 Colorado Convention Center - Exhibit Hall
No Clinically Relevant Effects of Hepatic Impairment on the Pharmacokinetics of a Next Generation Prodrug Troriluzole Monday 4/15/24: 11:45 - 12:45 P4 - Poster Session Colorado Convention Center - Exhibit Hall
Automated Video-based Characterization of Movement Quality in a Phase III Clinical Trial of Troriluzole in Subjects with Spinocerebellar Ataxia Tuesday 4/16/24: 8:00-9:00 P6- Poster Session 6 Colorado Convention Center Exhibit Hall
Psychometric Validation of the Modified-functional Scale for the Assessment and Rating of Ataxias Tuesday 4/16/24: 11:45-12:45 P7 Poster Session 7 Colorado Convention Center Exhibit Hall
Development of a Novel Composite Measure (SCACOMS) to Assess Disease Progression in Spinocerebellar Ataxia Tuesday 4/16/24: 11:45-12:45 P7 - Poster Session 7 Colorado Convention Center Exhibit Hall
Phase 1 Study Evaluating the Safety and Tolerability of BHV-7000, a Novel, Selective Kv7.2/7.3 Potassium Channel Activator, in Healthy Adults Tuesday 4/16/24: 5:30 - 6:30 P8 - Poster Session 8 Colorado Convention Center - Exhibit Hall
Novel, Selective Kv7.2/7.3 Potassium Channel Activator, BHV-7000, Demonstrates Dose-dependent Pharmacodynamic Effects on EEG Parameters in Healthy Adults
Tuesday 4/16/24: 5:30 - 6:30 P8 - Poster Session 8 Colorado Convention Center - Exhibit Hall
Determinants of Health-related Quality of Life of Patients with Focal Epilepsy: A Systematic Literature Review Wednesday 4/17/24: 8:00-9:00 P9- Poster Session 9 Colorado Convention Center Exhibit Hall
Characterization of BHV-7000: A Novel Kv7/2/7.3 Activator for the Treatment of Seizures Wednesday 4/17/24: 1:00-3:00 (2:00-2:12) S29- Epilepsy Diagnostics and Therapeutics Colorado Convention Center 605
Matching-adjusted Indirect Comparison of Troriluzole Versus Untreated Natural History Cohort in Spinocerebellar Ataxia Wednesday 4/17/24: 3:30-5:30 (5:06-5:18) S35 Movement Disorders: Hyperkinetic Movement Disorders Colorado Convention Center Four Seasons 4
Re-weighting MDS-UPDRS Part II Items for Optimal Sensitivity to Parkinson's Disease Progression Using Parkinson's Progression Markers Initiative Natural History Data Wednesday 4/17/24: 5:30-6:30 P11 Poster Session 11 Colorado Convention Center Exhibit Hall
Novel Bispecific Degrader BHV-1300 Achieves Rapid, Robust, and Selective IgG Reduction in Preclinical Models Including Nonhuman Primates Thursday 4/18/24: 1:00 - 3:00 (1:36-1:48) S43 - General Neurology 2 Colorado Convention Center - 108/110/112
SOURCE Biohaven Ltd.
Go here to see the original:
Biohaven Showcases Innovative Neuroscience Portfolio with 20 Presentations at the 2024 American Academy of ... - PR Newswire
What’s Going to Be Hot at ACC 2024 – TCTMD
Later this week, the American College of Cardiology (ACC) 2024 Scientific Session celebrates its 75th anniversary by heading back to Atlanta for the first time since 2010, with the plans to return in 2021 dashed by the COVID-19 pandemic. In this years lineup are some eagerly awaited cardiovascular trials in the drug and device space, but also some less traditional approaches assessing game-based and financial incentives, spirituality, and unique population approaches.
According to Douglas Drachman, MD (Massachusetts General Hospital, Boston), the scientific sessions chair, 2024 will be a blockbuster of a year for the meeting, which received 1,100 more abstracts than last year and the most its received in two decades, with submissions coming from 79 countries worldwide. There was truly global input into this meeting and certainly we hope for global impact, Drachman told a media telebriefing last week.
Late-Breaking Lineup
There will be a total of five late-breaking clinical trial (LBCT) sessions spread over the 3-day meeting. LBCT I, on Saturday, showcases just three trials: RELIEVE-HF, EMPACT-MI, and AEGIS II. This last trial, we already know from top-line results, came up empty-handed and in doing so delivered what might be a mortal blow to the HDL-raising hypothesis.
RELIEVE-HF, by contrast, is exploring newer terrain. This the second-ever randomized trial of an atrial shunt to relieve pulmonary pressure in heart failure: early positive signals reported 2 years ago raised some hopes that this trial might yield better results than REDUCE LAP-HF II, where a different atrial shunt device proved no better than a sham procedure for relieving pulmonary wedge pressures.
From my standpoint, Im hopeful that this allows us to advance the care of people who are still refractory, said Katie Berlacher, MD (University of Pittsburgh, PA), who serves as the meetings vice chair and co-moderated the briefing. There are many patients who we have, both with reduced and preserved ejection fraction, that despite many of our really good medical therapies, they either can't be on more because they don't tolerate more, or they're on the most and they are still having heart failure [symptoms]. So I'm incredibly curious about a structural change to the heart that then treats this.
Rounding out LBCT I is EMPACT-MI, testing empagliflozin (Jardiance; Boehringer Ingelheim/Eli Lilly) prescription immediately after acute MI to reduce subsequent MACE over usual care. Here, too, ACC attendees will be thinking of a predecessor: DAPA-MI, presented at last years American Heart Association meeting, which tested dapagliflozin (Farxiga; AstraZeneca) in acute MI and also came up empty-handed. Notably, however, DAPA-MI specifical excluded patients with diabetes, whereas EMPACT-MI did not.
Sunday morning features two late-breaking sessions. LBCT II, at 8 AM, features a mix of lipid-lowering trials, the phase II KARDIA-2 hypertension trial testing zilebesiran (Alnylam), and a novel approach using gamification, financial incentives, or both to induce patients at risk of adverse CV events to be more physically active.
LBCT III, at 11 AM, is dominated by MI and ACS trials, the most hotly anticipated being DANGER-SHOCK testing the Impella percutaneous transvalvular micro-axial flow pump (Abiomed) in patients presenting with acute MI complicated by cardiogenic shock. As previously reported by TCTMD, this trial has faced uphill battles enrolling and randomizing the sickest of patients, leading to a steady stream of imperfect, observational studies to try to fill the knowledge gap.
Other LBCT III trials also will likely make headlines. TACT2 is revisiting the enticing idea that chelation might help post-MI in patients with diabetes. REDUCE-AMI is tackling the long-running question of whether long-term beta-blockers are helpful after MI in patients with preserved ejection fraction, particularly in the current era of guideline-directed medical therapy. Lastly, the ULTIMATE DAPT trial is the latest trial to try to cut down on post-PCI antiplatelet therapy regimens, this time with a strategy of just 1-month of ticagrelor monotherapy after ACS.
A lone structural heart disease trial appears in that session: the SMART trial is comparing a balloon-expandable and a self-expanding TAVI valve in patients with small aortic annuli.
Cardiomyopathies get the spotlight Monday morning. LBCT IV features two new agents and one old, in this space. ARISE-HF tested a selective aldose reductase inhibitor (at-001; Applied Therapeutics) for the treatment of diabetic cardiomyopathy. IMPROVE-HCM examined ninerafaxstat (Imbria Pharmaceuticals), a novel cardiac mitotrope, in patients with symptomatic nonobstructive hypertrophic cardiomyopathy. PROACT, however, features an old drug, the ACE inhibitor enalapril, for the possibility of preventing anthracycline-induced cardiotoxicity in breast cancer and lymphoma patients. The last two trials in LBCT IV are a study of tranexamic acid to prevent seizures after cardiac surgery and TACTiC, testing a technology-assisted means of administering nonprescription rosuvastatin.
The last late-breaking session of ACC 2024 delivers an interventional cardiology wallop. LBCT V includes ORBITA-COSMIC, a placebo-procedure-controlled trial of a coronary sinus reducer for refractory angina; DEDICATE-DZHK6, pitting surgery against TAVI in low- and intermediate-risk patients; the Target BP I trial of renal denervation, an IVUS versus angiography to guide drug-coated balloon therapy in femoropopliteal artery disease; and preventive PCI versus medical therapy in patients with unstable coronary plaques. This last, said Drachman during the ACC press briefing, is sort of the Holy Grail of cardiologypreventing a future heart attack[and] I hope this trial will give more insights.
More Science
Each of the late breakers get a second look in deep-dive sessions scheduled later in the day each day. There are also three featured clinical research sessions, one per day, showcasing updates from recent trials or novel registry analyses.
Some outside-the-box studies have been grouped under the umbrella of Clinical and Investigative Horizons on Saturday and include a registry-based, decentralized trial addressing ways of providing more equitable cardiovascular care, a study of CVD risk factors among National Football League players and families, an implementation science study aimed at increasing heart failure therapies among members of the Navajo Nation, and a study gauging the effects of spirituality on blood pressure.
It's not all trials and science, of course, as the meetings CV Team Lead Kimberly Guibone, DNP (Beth Israel Deaconess Medical Center, Boston, MA), explained to the media. There are dedicated sessions focused on business of medicine concerns for healthcare professionals, 11 game show-style sessions complete with quizzes, lights, and buzzers, andby popular demandthe puppies are back for stressed out conference attendees to get their hands on.
For more on whats to come at ACC 2024, check out the latest Rox Heart Radio. The TCTMD team will be on-site in Atlanta. Please reach out with tips, complaints, and comments: we hope to see you there.
Read more:
Akoya Biosciences Showcases Spatial Biology 2.0 Solutions at AACR Annual Meeting with Case Studies … – GlobeNewswire
MARLBOROUGH, Mass., April 05, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (Nasdaq: AKYA), The Spatial Biology Company, today announced it will highlight case studies featuring its Spatial Biology 2.0 Solutions that enable unprecedented speed and scale for spatial biology studies at the American Association for Cancer Research (AACR) 2024 Annual Meeting in San Diego, April 5 to 10. In addition, the company will showcase new applications of its PhenoCode Signature Panels and preliminary data from the Thermo Fisher ViewRNA assays on Akoyas platforms.
Presentations Showcase the Power of Spatial Biology 2.0
Industry-leading capabilities of the companys spatial biology platforms will be presented during Akoyas Spotlight Theater, titled Spatial Biology 2.0: Spatial Insights and Precision Medicine at Unprecedented Scale on Monday, April 8 at 3 PM (PST). The event will describe how researchers are revealing new insights into the tumor microenvironment, elucidating the mechanisms of cancer treatment response, and paving the way for spatial biology to impact patient outcomes. Deployment of Akoyas PhenoCycler-Fusion 2.0, PhenoImager HT 2.0, and PhenoCode Panels across the research continuum, from ultrahigh-plex discoveries to actionable signatures, will be described by the presenters:
Dr. Kulasinghe will also present a talk entitled Ultra high-plex profiling of the tumor microenvironment on April 6 from 12:36 PM - 12:54 PM PT in Session MW14 - Choosing and Using Antibodies for Spatial Informed Protein Expression. He will discuss the development of ultrahigh-plex antibody panels for the comprehensive characterization of the tumor microenvironment.
Spatial Biology 2.0 Solutions Displayed at Booth #247
Akoya Biosciences will demonstrate new uses of its PhenoCode Signature Panels for accelerating discovery and validation of spatial biomarkers using the PhenoImager HT 2.0 platform. The company will also present initial findings from the Thermo Fisher Scientific ViewRNA assays on the PhenoCycler-Fusion 2.0.
Poster Presentations
Several studies featuring Akoyas Spatial Biology platforms will be described in the following posters:
Monday, April 8: 9:00 AM 12:30 PM
Poster 1525: Integration of high-plex tumor-Immune phenotyping and checkpoint interactions for deeper spatial characterization of human cancer tissues. S. Bodbin, Navinci Diagnostics et al.
Monday, April 8: 1:30 PM 5:00 PM
Poster 3623: Quantifying pharmacodynamic markers of radioligand therapies in tumor by multiplex immunofluorescence and automated quantitative analysis (AQUA) algorithms. J. Santos, Navigate BioPharma Services, Inc. et al.
Poster 3651: Mutational analysis and spatial phenotyping to decipher racial disparities in pancreatic adenocarcinoma; D. J. Salas-Escabillas, University of Michigan et al.
Poster 3763: Comparative spatial analyses of the tumor immune landscape in different mouse models of glioblastoma; D. Klymyshyn, Akoya Biosciences et al.
Tuesday, April 9: 9:00 AM 12:30 PM
Poster 3988: Deep spatial immunophenotyping of lymphoid aggregates in pancreatic cancer using multi-omic integration of ultra high-plex proteomics and transcriptomics; D. Gong, Massachusetts Institute of Technology (MIT) et al.
Poster 5503: Ultrahigh-plex spatial phenotyping of head and neck cancer tissue uncovers multiomic signatures of immunotherapy response; A. Pratapa, Akoya Biosciences et al.
Poster 5504: Integrating ultrahigh-plex spatial phenotyping: From discovery to clinical applications, A. Pratapa; Akoya Biosciences et al.
Tuesday, April 9: 1:30 PM 5:00 PM
Poster 5507: High-resolution spatial atlas reveals insight into spatial landscape of lung cancer and chronic lung diseases; R. Nandigama, Justus Liebig University et al.
Poster 5508: Single-cell spatial landscape of the mutation-specific human lung tumor immune microenvironment; R. Nandigama, Justus Liebig University et al.
Wednesday, April 10: 9:00 AM 12:30 PM
Poster 6738: Overlapping and distinct mechanisms of effective neoantigen cancer vaccines and immune checkpoint therapy; S. Keshari, UT MD Anderson Cancer Center et al.
Poster 6872: A spatio-temporal approach to mapping the dynamics of cutaneous squamous cell carcinoma progression and immunotherapy response: A journey through TiME; N. Jhaveri, Akoya Biosciences et al.
Network of CROs Providing Spatial Biology Services Continues to Grow
Thirteen of Akoyas twenty qualifiedCRO service providerswill also be exhibiting at AACR. Akoyas CRO network continues to grow rapidly, reflecting the demand for spatial phenotyping solutions across the biopharmaceutical industry. Offering biomarker testing services, these CROs enable drug developers and academic research institutions to accelerate the discovery and development of new immuno-therapies.
Full details about Akoyas AACR activities and poster presentations can be found here.
Forward Looking Statements
This press release contains forward-looking statements that are based on managements beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our expectations about the potential and utility of our products and services, the market demand for spatial phenotyping solutions and predictions regarding the future impact of spatial biology.
In some cases, you can identify forward-looking statements by the words may, will, could, would, should, expect, intend, plan, anticipate, believe, estimate, predict, project, potential, continue, ongoing or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.
About Akoya Biosciences
As The Spatial Biology Company, Akoya Biosciences mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The Company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. Akoya offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research: PhenoCode Panels and PhenoCycler, PhenoImager Fusion and PhenoImager HT Instruments. To learn more about Akoya, visitwww.akoyabio.com.
Investor Contact:
Priyam Shah Sr. Director, Investor Relations Akoya Biosciences investors@akoyabio.com
Media Contact:
Christine Quern 617-650-8497 media@akoyabio.com
Visit link: